Themis Medicare financials

Latest results Q1 FY27 · Apr–Jun 2026
Revenue
₹87.0cr−10.9% on Q1 FY26
Net profit
₹24.6cr−₹14.2 cr in Q1 FY26
EBITDA margin
−60.3%−49.9 pts on Q1 FY26
EPS
₹2.67−₹1.54 in Q1 FY26

Quarterly results

Every quarter ›
₹ croreQ1 FY27Q1 FY26Change
Revenue87.097.6−10.9%
EBITDA−52.4−10.1—
EBITDA margin−60.3%−10.3%−49.9 pts
Profit before tax36.0−13.9—
Net profit24.6−14.2—
EPS₹2.67−₹1.54—

Over time

Q1 FY27 · Apr–Jun 2026latest
Revenue₹87.0 crNet profit₹24.6 crNet margin28.3%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
907————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
4.54.56.69.912.5
−0.0−0.0−0.0−0.0−0.0
10010083.095.892.0
1,002————
332342406382354
—−15.6%+6.2%+7.7%—
−41.90.449.051.567.5
−12.6%0.1%12.1%13.5%19.0%
−52.3−9.939.139.357.0
40.01.129.843.556.9
12.1%0.3%7.4%11.4%16.1%
₹4.34₹0.12₹3.24₹4.73₹6.18
—−96.2%−31.5%−23.5%—
—−3.334.714.516.1
—−4.9−15.4−18.4−28.7
−8.1−8.119.3−4.0−12.7
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

THEMISMED₹98.44

Themis Medicare Limited

· Pharma & Health
₹ CrorePeersLINCOLNBAJAJHCARESIGACHIWANBURYAMRUTANJANAHCLANUHPHRMcap ₹907 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————906.6
- Cash, Equiv & ST Investments12.59.96.64.54.5
+ Minority Interest-0.0-0.0-0.0-0.0-0.0
+ Total Debt92.095.883.0100.1100.1
Enterprise Value————1,002.2
Revenue354.3381.8405.5342.2331.6
Growth %, YoY—+7.7+6.2-15.6—
EBITDA67.551.549.00.4-41.9
Margin %19.0413.4912.100.11-12.65
EBIT57.039.339.1-9.9-52.3
Net Income56.943.529.81.140.0
Margin %16.0611.407.360.3312.05
EPS, Adj (current shares)6.184.733.240.124.34
Growth %, YoY—-23.5-31.5-96.2—
Cash from Operations16.114.534.7-3.3—
Capital Expenditures-28.7-18.4-15.4-4.9—
Free Cash Flow-12.7-4.019.3-8.1-8.1
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Themis Medicare financials and key ratios

Prices at the 29 October 2026 close · figures from the company's filings with NSE

Themis Medicare (NSE: THEMISMED) had a market capitalisation of ₹898 crore at the 29 October 2026 close (₹97.52 a share), a PE ratio of 22.5 on the last four quarters' profit and a price-to-book ratio of 2.25. In FY26 its consolidated net profit was ₹1.1 crore on revenue of ₹342 crore; in Q1 FY27 (April–June 2026) it was ₹24.6 crore. Its debt-to-equity ratio was 0.25 on 31 March 2026. Promoters held 67.11% of the shares on 30 September 2026.

Share price used
₹97.52 · 29 October 2026 close
Latest balance sheet
31 March 2026
Shareholding pattern
30 September 2026

Themis Medicare at a glance · consolidated

Market cap
₹898 Crat ₹97.52 · 29 Oct close
PE ratio (last 4 quarters)
22.5785.2 on FY26 profit
Price to book (PB)
2.25book value ₹43.28 a share
ROE (FY26)
0.3%−7.4 pts vs FY25ROCE −2.3%
Debt to equity
0.25net debt ₹90.9 Cr
Promoter holding
67.11%unchanged vs 30 Jun 202630 September 2026
Dividend yield
0.51%₹0.50 a share in 12 months
Net worth
₹399 Cr−1.0% vs 31 Mar 202531 March 2026
Free cash flow (FY26)
−₹8.1 Cr

Questions

What is the Themis Medicare PE ratio today?

Themis Medicare's PE ratio is 22.5 at the 29 October 2026 close (₹97.52 a share): a market capitalisation of ₹898 crore divided by consolidated net profit of ₹40 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit (₹1.1 crore) it is 785.2. These four quarters include net exceptional items of ₹92.1 crore (one-off gains reported separately), so the ratio on recurring profit would differ.

What is the Themis Medicare PB ratio (price to book value)?

Themis Medicare's price-to-book (PB) ratio is 2.25 at the 29 October 2026 close: a market capitalisation of ₹898 crore divided by shareholders' equity (book value) of ₹399 crore on 31 March 2026. That is a book value of ₹43.28 per share against a share price of ₹97.52.

What is the Themis Medicare ROE and ROCE?

In FY26, Themis Medicare's return on equity (ROE) was 0.3% and its return on capital employed (ROCE) was −2.3%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 7.7% and ROCE 9.3%.

What is the Themis Medicare market cap?

Themis Medicare's market capitalisation was ₹898 crore at the 29 October 2026 close: 9.21 crore shares at ₹97.52 each.

What is the Themis Medicare EPS?

Themis Medicare's basic earnings per share (EPS) were ₹0.12 in FY26, against ₹3.24 in FY25. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹4.34.

What is the Themis Medicare dividend in 2026 and its record date?

In 2026, Themis Medicare has declared one dividend: ₹0.50 with record date 23 September 2026.

Is Themis Medicare debt free?

No. Themis Medicare had borrowings of ₹100 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.25. Its cash and current investments were ₹9.1 crore, so its net debt was ₹90.9 crore.

What is the Themis Medicare debt to equity ratio?

Themis Medicare's debt-to-equity ratio was 0.25 on 31 March 2026: borrowings of ₹100 crore against total equity of ₹399 crore. A year earlier, on 31 March 2025, it was 0.21.

What is the Themis Medicare promoter holding?

Promoters held 67.11% of Themis Medicare on 30 September 2026, unchanged from the previous quarter and down 0.04 percentage points from 67.15% a year earlier, according to the shareholding pattern filed with NSE.

What is the Themis Medicare net worth?

Themis Medicare's net worth — shareholders' equity in its consolidated balance sheet — was ₹399 crore on 31 March 2026, down 1.0% from ₹403 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹898 crore at the 29 October 2026 close.

What is the Themis Medicare dividend yield?

Themis Medicare's dividend yield is 0.51% at the 29 October 2026 close: dividends of ₹0.50 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹97.52. They were ₹0.50 on 23 September 2026.

What is the Themis Medicare free cash flow?

In FY26, Themis Medicare generated ₹3.3 crore of cash from operations and spent ₹4.9 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹8.1 crore. In FY25 it was ₹19.3 crore.

What is the Themis Medicare book value per share?

Themis Medicare's book value per share was ₹43.28 on 31 March 2026: shareholders' equity of ₹399 crore divided by the 9.21 crore shares in issue, down 1.1% from ₹43.74 a year earlier. The share price at the 29 October 2026 close was ₹97.52.

What are the Themis Medicare latest quarterly results?

Themis Medicare's latest results are for Q1 FY27 (April–June 2026), filed on 13 August 2026: consolidated net profit ₹24.6 crore, against a loss of ₹14.2 crore in Q1 FY26; revenue from operations ₹87 crore, down 10.9% year on year.

What is the Themis Medicare revenue and profit in FY26?

In FY26 (April 2025–March 2026), Themis Medicare's consolidated net profit was ₹1.1 crore, down 96.2% from ₹29.8 crore in FY25, on revenue from operations of ₹342 crore (down 15.6%). Over three years, from FY23, net profit was down 98.0%.

What is the Themis Medicare shareholding pattern?

On 30 September 2026, Themis Medicare's shares were held by promoters 67.11%, foreign portfolio investors (FII/FPI) 0.01%, domestic institutions (DII) 0.01% (including mutual funds at 0.00%) and retail and other non-institutional investors 32.87%. Over the year, FII holding was down 0.05 percentage points from 0.06% and DII holding was unchanged.

When are the Themis Medicare next results?

Themis Medicare will announce its Q2 FY27 results (July–September 2026) on Thursday, 5 November 2026, the date of the board meeting it has notified to the exchanges.

Themis Medicare vs Lincoln Pharmaceuticals: how do they compare?

In FY26, Themis Medicare earned net profit of ₹1.1 crore on revenue of ₹342 crore, against ₹87.9 crore on ₹671 crore for Lincoln Pharmaceuticals. Themis Medicare's operating margin was −2.9% (Lincoln Pharmaceuticals 12.4%) and its return on equity 0.3% (Lincoln Pharmaceuticals 12.3%). At the 29 October 2026 close, Themis Medicare's market capitalisation was ₹898 crore against ₹1,021 crore for Lincoln Pharmaceuticals, and its PE ratio on FY26 profit 785.2 against 11.6.

How does Themis Medicare compare with its peers?

On FY26 consolidated figures, against Lincoln Pharmaceuticals, Bajaj Healthcare and Sigachi Industries: Themis Medicare's operating margin of −2.9% is the lowest of the four (Lincoln Pharmaceuticals 12.4%, Bajaj Healthcare 12.7%, Sigachi Industries 7.6%; peer average 10.9%); its return on equity of 0.3% is the third highest of the four (Lincoln Pharmaceuticals 12.3%, Bajaj Healthcare 3.2%, Sigachi Industries −14.6%; peer average 0.3%); its revenue growth over three years of −1.2% a year is the third highest of the four (Lincoln Pharmaceuticals 9.6% a year, Bajaj Healthcare −3.2% a year, Sigachi Industries 16.5% a year; peer average 7.6% a year).

Where do these Themis Medicare figures come from?

From Themis Medicare's own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.